211 related articles for article (PubMed ID: 12012125)
1. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
4. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
5. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.
Delgrange E; Trouillas J; Maiter D; Donckier J; Tourniaire J
J Clin Endocrinol Metab; 1997 Jul; 82(7):2102-7. PubMed ID: 9215279
[TBL] [Abstract][Full Text] [Related]
6. Gender-related differences in prolactinomas. A clinicopathological study.
Schaller B
Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
[TBL] [Abstract][Full Text] [Related]
7. [Invasive giant prolactinoma].
Domínguez Ugidos LJ; Martínez Subías J; Urpegui García A; Sancho Serrano E; Alfonso Collado JI; Vallés Varela H
Acta Otorrinolaringol Esp; 1998 Mar; 49(2):156-8. PubMed ID: 9650316
[TBL] [Abstract][Full Text] [Related]
8. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
9. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
10. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunohistochemical analysis of estrogen receptor and chromogranin-A reactivity in plurihormonal human prolactinomas.
Talan-Hranilović J; Gnjidić Z; Sajko T; Vizner B; Vrkljan M
Acta Med Croatica; 2000; 54(2):59-63. PubMed ID: 11028110
[TBL] [Abstract][Full Text] [Related]
12. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Passos VQ; Souza JJ; Musolino NR; Bronstein MD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
[TBL] [Abstract][Full Text] [Related]
14. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma.
Trouillas J; Girod C; Claustrat B; Joly-Pharaboz MO; Chevallier P
Cancer Res; 1990 Jul; 50(13):4081-6. PubMed ID: 2354457
[TBL] [Abstract][Full Text] [Related]
16. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
17. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effects of melatonin on the development of 17-beta-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents].
Gao L; Xu JP; Shan HM; Zhang R; Xu RK
Sheng Li Xue Bao; 2001 Jun; 53(3):165-9. PubMed ID: 12589398
[TBL] [Abstract][Full Text] [Related]
19. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
20. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
